Emerging technologies focused on
Improving Patient Outcomes
for cost effective healthcare


Our Mission

Although there has been great advances in the understanding and treatment of cancer, this disease today is largely detected and diagnosed with the same procedures and technology that has been used for generations. The same is true for measuring an individual’s response to therapy. These methods are inefficient, painful and expensive. NuView wants to change this. We are developing a compelling and innovative way to detect, diagnose and personalize the treatment of cancer.
Read the ebook:
Cancer Specific Molecular Biomarkers

Strong IP Pipeline

  • Urine screen to detect prostate and bladder cancer
  • Imaging agent to diagnose prostate and breast cancer
  • Imaging agent to assess tumor response to therapy


  • Replace PSA testing with accurate and early detection
  • Eliminate invasive diagnostic procedures by visualizing disease
  • Personalize therapies with rapid assessment of tumor response


What is PET Imaging?

Images produced from new medical technologies that incorporate PET (positron emission tomography) are similar to a weather map you see on your local news.

Play Video

Read More


Our NLS-VPAC1 Technology Platform

Our patented imaging agent binds to a receptor (called VPAC1) on the surface of many cancer cells.   We are utilizing this technology to create a urine screen to detect prostate/bladder cancer and an imaging agent to transform the diagnosis of breast and prostate cancer.

Learn more


Our NLS-FMAU Imaging Agent

Our patented imaging agent directly visualizes the cellular proliferation of a tumor.  We are developing this product to rapidly assess an individual’s response to cancer therapy.

Learn more

Market Readiness Progress (at 100%)

NLS-VPAC1 - Prostate / Bladder Cancer Urine Screen @ Analytical Validation

NLS-VPAC1 - Breast Cancer Imaging @ Phase 1

NLS-VPAC1 - Prostate Cancer Imaging @ Phase 1 Ongoing

NLS-FMAU - Cancer Tumor Treatment Planning and Therapy Response @ Phase 1 Ongoing

Management Team

  • Paul Crowe

    Chairman & CEO

    About Paul Crowe

    Mr. Crowe is the founder of NuView Life Sciences and has served as Chairman and Chief Executive Officer since 2005. Mr. Crowe’s experience includes early-stage company development, strategic planning, capital formation, M&A, and public offerings. Over the past 40 years, Mr. Crowe has commercialized novel medical imaging technologies, such as diagnostic ultrasound with Philips Medical Systems, magnetic resonance imaging (MRI) with Diasonics NMR and positron emission tomography (PET) with Mobile PET Systems. Mr. Crowe developed several medical service provider businesses utilizing the technologies described above building high-performance management, sales and operations teams to drive technology adoption and revenue growth.

  • Thomas Brown

    Vice President Finance

    About Thomas Brown

    Mr. Brown has over 40 years of business and financial experience in the analysis, structuring and sourcing of capital, valuation, repositioning/restructuring and the management of financial/operating assets, as well as, businesses. Mr. Brown is the founding partner of three investment-banking firms, a private equity firm, and two investment management firms. Mr. Brown has served as the CFO of several public and private companies, as well as, non-profit organization and focused on coordinating the reporting and management of the financial infrastructure for emerging growth businesses and organizations. In addition to serving on the board of several public, private and non-profit organizations, Mr. Brown has been the chairman of the audit committees of several public companies.   Mr. Brown graduated from the University of Southern California with a B.S. in Finance and earned the Chartered Financial Analyst (CFA) designation.  Mr. Brown is an Adjunct Professor in the Argyros School of Business & Finance at Chapman University where he teaches Entrepreneurial Finance.

  • Steven J. Davis

    Legal Counsel

    About Steven J. Davis

    Mr. Davis has over twenty years’ experience in corporate, securities, and business law, with extensive experience in emerging growth companies.  Mr. Davis is also a founding partner of Rancho Santa Fe Partners, a strategic advisory firm that supports emerging growth companies.  Mr. Davis has served as General Counsel and an executive officer for several public and privately held companies, and has clients which include International Stem Cell (ISCO), Amylin Pharmaceuticals (AMLN), Leap Wireless (LEAP), BillMyParents (BMPI), Mitek (MITK), and SugarMade (SGMD).  Mr. Davis is on the Board of Directors and Audit, Compensation and Nominating Committees (Chairman) of Telanetix (TNIX), a publicly traded telecommunications company, and on the Board of Directors of Theragene, a privately held life sciences company.  Mr. Davis practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP, where he advised both private and public clients in a variety of transactions.  Mr. Davis received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law. He received his B.A. in Political Science, Cum Laude, from Arizona State University.

  • Peter S. Conti, MD

    Medical Director

    About Peter S. Conti, MD

    Dr. Conti has served as the Company’s Medical Director and Director of the Company since October 2004.  Dr. Conti is a Professor of Radiology, Pharmacy, and Biomedical Engineering at the University of Southern California, as well as Director of its Positron Imaging Science Center and Clinic. Dr. Conti received his medical degree from Cornell University and completed his residency in Diagnostic Radiology and fellowship in Nuclear Medicine at The Johns Hopkins Medical Institution. He is board-certified in both Diagnostic Radiology and Nuclear Medicine. Dr. Conti currently serves on the Board of Directors and is a past-president of the Society of Nuclear Medicine (SNM). Dr Conti also serves on a number of committees for the SNM that is focused on the development of the PET technology and its applications in medicine, including those involving government and regulatory affairs.

  • Stuart Foster


    About Stuart Foster

    Mr. Foster brings to the Company’s board a strong engineering and management background in various aspects of the healthcare industry. From 2000-2008, Mr. Foster served as Corporate Vice President of Edwards Life Sciences and was part of the executive team that managed the spin-off of Edwards from Baxter International into a NYSE listed company in April 2001. Mr. Foster was president of Global Operations for Baxter International from 1994 to 2000, where he managed the vascular and critical care business. From 1990 to 1994, Mr. Foster was president of Intramed Laboratories, a venture funded development Stage Company, which was focused on developing  technology for disposable endoscopy products that subsequently went public and was sold to Baxter International. In 1983 to 1989, he was vice president and general manager of Sensor medics, the advanced technology operations group of Beckman Instruments, where he coordinated a leverage buyout of the business that became the leader in anesthesia monitoring and exercise physiology equipment and was subsequently sold to Thermo-Electron. He holds a BS in Biomedical engineering from Renssalear Polytechnic Institute and an MS in Biomedical engineering from the University of Southern California. In addition to serving on the board of NuView, he serves on the advisory board for the Rennselaer School of Engineering.  He currently resides in Park City, Utah and La Quinta, California.

  • Thomas McCausland


    About Thomas McCausland

    Mr. McCausland joined the Company as a Director in October 2007. Over Mr. McCausland’s 40-year business career, he has served in senior executive positions with Westinghouse Electric Corporation and Siemens. From 1997 through 2006, he served as President of the Siemens Medical Customer Solutions Group and grew revenues from $1 billion to over $4 billion during his tenure. In addition to serving as an advisor to the Radiological Society of North America and several other healthcare companies, Mr. McCausland also served as chairman of the Siemens Foundation dedicated to improving math and science education in high schools.

  • Michael Nobel PH.D.


    About Michael Nobel PH.D.

    Michael Nobel participated in the introduction of magnetic resonance imaging in 1980 and remained in that field for 26 years. Today he is chairman or board member of seven international companies in diagnostics, treatment and information systems in the field of medicine.

    For 15 years Michael Nobel represented the Nobel family as vice chairman and chairman of its board of directors. He is founder and chairman of the Nobel Sustainable Trust.  He is chairman or board member of eight non-for-profit organizations in the field of youth education and development and peace and conflict resolution.

    Michael Nobel was visiting professor at the Frontier Research Institute at the Tokyo Institute of Technology between 2007 and 2012. He is currently a senior fellow at the Centre for the Study of World Civilizations at Tokyo Tech and a guest professor at Seisa University.

    In 2005 in Jerusalem he received the Albert Einstein Medal for Outstanding Achievements in Life Sciences and Technology and in 2006 the International Order of Perfection in Moscow. In 2013 he received the Order of Duty and Honor from the United Nations Council for Public Awards and the Gold Medal from the IINC in Tambov, Russia. The World Federation of Consuls presented him its Order of Merit in 2014.

    Michael Nobel obtained a doctorate at the University of Lausanne in psycho-pedagogy.

  • Maury DeWald, CPA


    About Maury DeWald, CPA

    Maurice DeWald has served as the Chairman and CEO of Verity Financial Group, Inc., since 1992, where the primary focus has been in healthcare and technology sectors. He also serves as a director of public companies Healthcare Trust of America, Inc., Targeted Medical Pharma, Inc. and Emmaus Life Sciences, Inc., and as a non-executive Chairman of public company Integrated Healthcare Holdings, Inc. DeWald previously served as a director of Tenet Healthcare Corporation, ARV Assisted Living, Inc. and Quality Systems, Inc. From 1962 to 1991, DeWald was employed by KPMG, LLP, where he served at various times as an audit partner, a member of their board of directors, as well as the managing partner.

  • William G. Bradley, Jr. MD


    About William G. Bradley, Jr. MD

    Dr. Bradley serves as a consultant facilitating the needs for the new MRI/PET integrated imaging systems now beginning to be shipped from the major medical device manufactures. Dr. Bradley is Chairman of the Department of Radiology at the University of California, San Diego since 2002. Dr. Bradley received his B.S. at the California Institute of Technology and his Ph.D. at Princeton University, both in Chemical Engineering. Dr. Bradley completed all of his medical training at the University of California, San Francisco. Dr. Bradley was the Director of MRI at both the Huntington Medical Research Institute from 1982 to 1989 and Long Beach Memorial Medical Center from 1990 to 2002. Dr. Bradley was also Professor of Radiology at UC Irvine from 1994 to 2002. He is past-president of the International Society of Magnetic Resonance in Medicine and has won its two highest honors for his research, the Gold Medal and Honorary Member.

  • Kimberley Labertew

    Business Development

    About Kimberley Labertew

    Ms. Labertew has over 25 years of strategy and operations experience working as a senior strategy consultant and business improvement leader to Fortune 100 and 500 companies. Ms. Labertew is an innovative, executive-level leader with diverse, real-world experience in driving business performance results through building internal capabilities. She was a senior management consultant for Booz Allen & Hamilton and CSC Index providing a variety of strategic and operational advisory services including New Business Strategy, Operations Process Optimization and Leadership Development in a wide variety of industries including Manufacturing, Financial Services and Information Technology. Working as the Business Improvement Manager at Dyno Nobel, she led the Program Office for supply chain, manufacturing and corporate areas that delivered greater than $120M in EBIT benefits over four years. As the Global Best Practices Leader for Incitec Pivot Ltd, Kimberley selected, trained and coached a global network to implement World Class Manufacturing and Lean practices, including 5S, Teamwork, Visual Management, Focused Improvement, SMED, Warehousing and Transactional Excellence. Ms. Labertew graduated from Middlebury College with a B.S. in Political Science and earned an MBA from Westminster College.

The NLS-VPAC1 is a powerful tool to detect and visualize a variety of cancers at the earliest stage of disease.




Clinical Research Associate Position

The primary role of the CRA will be to support the clinical development
of a novel PET imaging agent that will be used in the diagnosis of cancer.
Reporting to the Clinical Research Manager, the CRA is primarily responsible for the..
Learn more

Want to Learn More About NuView?

We welcome inquiries with interested individuals, media and potential investors. Please drop us a note in the contact form or call us directly.

Contact Address

NuView Life Sciences, Inc
1389 Center Drive, Suite 250
Park City, Utah 84098

Contact Details

TEL 888.902.7779
FAX 435.647.5602

Office Hours

9am to 5pm MST
Monday to Friday